Match!

Screening for Prostate Cancer Starting at Age 50–54 Years. A Population-based Cohort Study

Published on Jan 1, 2017in European Urology17.30
· DOI :10.1016/j.eururo.2016.03.026
Sigrid Carlsson26
Estimated H-index: 26
(MSK: Memorial Sloan Kettering Cancer Center),
Melissa Assel12
Estimated H-index: 12
(MSK: Memorial Sloan Kettering Cancer Center)
+ 4 AuthorsHans Lilja80
Estimated H-index: 80
(University of Oxford)
Abstract
Abstract Background Current prostate cancer screening guidelines conflict with respect to the age at which to initiate screening. Objective To evaluate the effect of prostate-specific antigen (PSA) screening versus zero screening, starting at age 50–54 yr, on prostate cancer mortality. Design, setting, and participants This is a population-based cohort study comparing 3479 men aged 50 yr through 54 yr randomized to PSA-screening in the Goteborg population-based prostate cancer screening trial, initiated in 1995, versus 4060 unscreened men aged 51–55 yr providing cryopreserved blood in the population-based Malmo Preventive Project in the pre-PSA era, during 1982–1985. Outcome measurements and statistical analysis Cumulative incidence and incidence rate ratios of prostate cancer diagnosis, metastasis, and prostate cancer death. Results and limitations At 17 yr, regular PSA-screening in Goteborg of men in their early 50s carried a more than two-fold higher risk of prostate cancer diagnosis compared with the unscreened men in Malmo (incidence rate ratio [IRR] 2.56, 95% confidence interval [CI] 2.18, 3.02), but resulted in a substantial decrease in the risk of metastases (IRR 0.43, 95% CI 0.22, 0.79) and prostate cancer death (IRR 0.29, 95% CI 0.11, 0.67). There were 57 fewer prostate cancer deaths per 10000 men (95% CI 22, 92) in the screened group. At 17 yr, the number needed to invite to PSA-screening and the number needed to diagnose to prevent one prostate cancer death was 176 and 16, respectively. The study is limited by lack of treatment information and the comparison of the two different birth cohorts. Conclusions PSA screening for prostate cancer can decrease prostate cancer mortality among men aged 50–54 yr, with the number needed to invite and number needed to detect to prevent one prostate cancer death comparable to those previously reported from the European Randomized Study of Screening for Prostate Cancer for men aged 55–69 yr, at a similar follow-up. Guideline groups could consider whether guidelines for PSA screening should recommend starting no later than at ages 50–54 yr. Patient summary Guideline recommendations about the age to start prostate-specific antigen screening could be discussed.
  • References (26)
  • Citations (14)
References26
Newest
#1Andrew J. Vickers A J (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 92
#2James A. Eastham (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 90
Last.Hans Lilja (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 80
view all 4 authors...
28 CitationsSource
#1Rebecka Arnsrud Godtman (University of Gothenburg)H-Index: 7
#2Erik Holmberg (University of Gothenburg)H-Index: 35
Last.Jonas Hugosson (University of Gothenburg)H-Index: 50
view all 5 authors...
50 CitationsSource
#1Matthew R. Cooperberg (UCSF: University of California, San Francisco)H-Index: 55
#2Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 112
301 CitationsSource
#1Paul R. Womble (UM: University of Michigan)H-Index: 8
#2James E. Montie (UM: University of Michigan)H-Index: 66
Last.David C. Miller (UM: University of Michigan)H-Index: 41
view all 6 authors...
125 CitationsSource
#1Fritz H. Schröder (Erasmus University Medical Center)H-Index: 89
#2Jonas Hugosson (University of Gothenburg)H-Index: 50
Last.Anssi Auvinen (RMIT: RMIT University)H-Index: 73
view all 29 authors...
656 CitationsSource
#1Sigrid Carlsson (University of Gothenburg)H-Index: 26
#2Melissa Assel (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 12
Last.Andrew J. Vickers A J (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 92
view all 7 authors...
57 CitationsSource
28 CitationsSource
#1Robert A. Smith (ACS: American Cancer Society)H-Index: 81
#2Deana Manassaram‐Baptiste (ACS: American Cancer Society)H-Index: 8
Last.Otis W. Brawley (ACS: American Cancer Society)H-Index: 46
view all 8 authors...
116 CitationsSource
#1Axel Heidenreich (RWTH Aachen University)H-Index: 59
#2Per-Anders Abrahamsson (Lund University)H-Index: 42
Last.Nicolas MottetH-Index: 31
view all 8 authors...
110 CitationsSource
#1H. Ballentine Carter (American Urological Association)H-Index: 67
#2Peter C. Albertsen (American Urological Association)H-Index: 63
Last.Anthony L. Zietman (American Urological Association)H-Index: 69
view all 12 authors...
674 CitationsSource
Cited By14
Newest
#1David Andrés Castañeda-Millán (National University of Colombia)H-Index: 2
#2Cesar Andrés Capera-López (National University of Colombia)
Last.Wilfredo Donoso-Donoso (National University of Colombia)
view all 5 authors...
Source
#1Giorgio Gandaglia (UniSR: Vita-Salute San Raffaele University)H-Index: 31
#2Peter Albers (HHU: University of Düsseldorf)H-Index: 43
Last.Hein Van Poppel (Katholieke Universiteit Leuven)H-Index: 73
view all 12 authors...
5 CitationsSource
#1Alireza Aminsharifi (Duke University)H-Index: 12
#2Ariel Schulman (Durham University)H-Index: 4
Last.Thomas J. Polascik (Duke University)H-Index: 51
view all 10 authors...
Source
#1Maria Frånlund (Sahlgrenska University Hospital)H-Index: 4
#2Rebecka Arnsrud Godtman (Sahlgrenska University Hospital)H-Index: 7
Last.Jonas Hugosson (Sahlgrenska University Hospital)H-Index: 50
view all 7 authors...
1 CitationsSource
#1Takeshi Hashimoto (TMU: Tokyo Medical University)H-Index: 9
#2Makoto Ohori (TMU: Tokyo Medical University)H-Index: 15
Last.Yoshio Ohno (TMU: Tokyo Medical University)H-Index: 15
view all 10 authors...
1 CitationsSource
#1Richard M. Martin (UoB: University of Bristol)H-Index: 102
#2Jenny L Donovan (NIHR: National Institute for Health Research)H-Index: 82
Last.Freddie C. Hamdy (University of Oxford)H-Index: 71
view all 26 authors...
63 CitationsSource
Last.Harry J. de KoningH-Index: 71
view all 3 authors...
2 CitationsSource
#1Jonas Hugosson (Sahlgrenska University Hospital)H-Index: 50
#2Rebecka Arnsrud Godtman (Sahlgrenska University Hospital)H-Index: 7
Last.Hans Lilja (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 80
view all 10 authors...
6 CitationsSource
#1Amilcar Flores-Morales (UCPH: University of Copenhagen)H-Index: 31
#2Diego Iglesias-Gato (UCPH: University of Copenhagen)H-Index: 9
6 CitationsSource
#1Christiane K. KuhlH-Index: 50
#2Robin BruhnH-Index: 3
Last.Simone SchradingH-Index: 14
view all 6 authors...
50 CitationsSource
View next paperScreening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up